The business club reported on July 1 that Chinese medicine was blocked from going abroad. Since May of this year, the EU's "Traditional Plant Drugs Directive" has officially ended its transitional period. At present, there are about 350 kinds of plant medicines registered in various countries and regions. However, none of the Chinese medicines known as the "Botanical Medicine Grand View Garden" has been registered. This means that Chinese medicine cannot be used as a drug sale in the European Union. Chinese medicine was "rejected." The EU has sighed at home and some people are not convinced. Why are the same botanical drugs, other countries can register, we can not pass, from which to reflect the bottlenecks of Chinese medicine development?

One bottleneck: The efficacy of drugs could not be explained in a 7-year transitional period, and none of the Chinese medicines were registered. In the face of the "answers," many people in the industry feel that the EU's high "registration threshold" is an obstacle. According to EU regulations, registered herbs must have 30 years of pharmaceutical history outside the EU and 15 years of medicinal history in the EU. The cost problem is even more obvious. The registration fee for a Chinese medicine variety needs to be more than 800,000 yuan, and the hardware investment for production equipment and the like needs more than 4 million yuan. The accumulative cost is unbearable for many Chinese medicine companies.
Is the EU's "registration threshold" really too high? Professor Chen Wei of the Shanghai Association of Chinese and Western Medicine and Longhua Hospital believes that the threshold of these aspects is not the root cause of the problem. According to this line of thought, in the future, when companies register to enlarge their businesses and increase input, they will only “do additions” from the technical operation level, and they will only be able to enter the wrong area and find no way out. The real problem lies in the ambiguity of traditional Chinese medicines from research and development to efficacy. In fact, many western medical experts do not reject traditional Chinese medicines. It does not matter whether a single herb or a compound medicine is used. However, the key is to provide an excellent therapeutic effect. The lack of standardized drug development procedures and the lack of complete drug descriptions are precisely where the weaknesses of traditional Chinese medicine lie. The lack of conclusive explanations for the direct use of drugs in the human body is not justified.

Bottleneck 2: R & D and production of non-standardized Chinese medicines lacks refined efficacy, which not only hinders them from going abroad, but also limits the development of Chinese medicine. Domestic patients emotionally approve Chinese medicine, but this cannot hide the gap between traditional Chinese medicine and modern medical evaluation systems. Some traditional Chinese medicines can be "all-embracing", and some have symptoms that correspond to many diseases....Chinese medicines have too many indications, lack of correlation, too ambiguous efficacy descriptions, and unrecognized side effects, which make them difficult for patients. And experts are not convincing.
To go abroad, Chinese medicine must increase its modern content. Experts said that the development of Chinese medicine should seriously reflect on its own problems. Specifically, at present, Chinese proprietary Chinese medicines are still lacking in the process of R&D, manufacturing, and marketing; many R&D of TCM are based on the experience side and “followed up”, corresponding animal studies, and toxicology. The research report is not sufficient, and these are far from the international requirements for drug development. To boost the development of traditional Chinese medicine, the government has the responsibility to make great efforts to unite research institutes, medical institutions, and drug companies to get through the "joint" in the traditional Chinese medicine system and the modern medical system, consolidating the "modernization" connotation of traditional Chinese medicine.

Bottleneck 3: Inadequate promotion model At present, plant medicines in countries such as Japan, South Korea and South Africa have entered the EU and US markets. There are no shortages of raw materials imported from China, and these countries have passed internationally recognized standards analysis and inspections. The door to the western market. Experts said that "stones from other hills" should be a model for our study. In addition to meeting international standards in the drug research and development field, these countries are also worthy of reference for their marketing methods and propaganda methods.
The sale of Chinese medicine abroad is confined to the Chinese coterie; for the unique theoretical system of traditional Chinese medicine, Western medicine is still doubtful. Professor Chen Wei believes that if the theoretical system of Chinese medicine is to be successfully exported to foreign countries, it should also reverse the philosophical expression of "mysterious and mysterious" and use the expressions familiar to Western medicine to "translate." In accordance with the Western population's thinking patterns and market needs, Chinese medicine must be carefully designed to promote marketing. Only by allowing western experts and the public to identify with the theoretical system, can we have a more intuitive understanding of Chinese medicine and pave the way for Chinese medicine to go global and develop. (Reporter Gu Yong)